Prescribing trends in bipolar disorder: Cohort study in the united kingdom thin primary care database 1995-2009

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Hayes, Joseph ^a   Prah, Philip ^b   Nazareth, Irwin ^a,b   King, Michael ^a   Walters, Kate ^a   Petersen, Irene ^a   Osborn, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; TRANQUILIZER;

ADULT; AGE; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG USE; FEMALE; GENDER; HEALTH IMPROVEMENT NETWORK PRIMARY CARE DATABASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PATIENT IDENTIFICATION; PRESCRIPTION; PRIMARY MEDICAL CARE; SAMPLE SIZE; SOCIAL ISOLATION; UNITED KINGDOM; ADOLESCENT; CLINICAL PRACTICE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY; SOCIAL CLASS; TIME;

ADOLESCENT; ADULT; AGED; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COHORT STUDIES; DIBENZOTHIAZEPINES; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SOCIAL CLASS; TIME FACTORS; VALPROIC ACID;

EID: 82855177853     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028725     Document Type: Article

References (46)

1. Goodwin GM, (2009) Evidence-based guidelines for treating bipolar disorder: revised second edition- recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 23 (4): 346-388.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington (DC) American Psychiatric Association.
3. Baldessarini RJ, (2002) Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 2002;16: 721-729.
4. NICE (2006) Bipolar disorder The management of Bipolar disorder in Adults, children and adolescents in Secondary and Primary care. Nice Guideline 38.
5. Maudsley Prescribing Guidelines (2009) 10th Edition England Informa Healthcare.
6. Keck PE Jr, Perlis RH, Otto MW, Carpenter D, Ross R, et al. (2004) The Expert Consensus Guidelines: Treatment of Bipolar Disorder 2004. Postgrad Med Special Report (December) pp. 1-120.
7. Frangou S, Raymont V, Bettany D, (2002) The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disorder 4: 378-385.
8. Levine J, Chengappa KNR, Brar JS, Gershon S, Yablonsky E, et al. (2000) Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disorder 2: 120-130.
9. Fenn HH, Robinson D, Luby V, Dangel C, Buxton E, et al. (1996) Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 153: 711-713.
10. Citrome L, Levine J, Allingham B, (1998) Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr Q 69: 283-300.
11. Crump BJ, Panton R, Drummond MF, Marchment M, Hawkes RA, et al. (1995) Transferring the costs of expensive treatments from secondary to primary care. BMJ 310 (6978): 509-512.
12. Osborn PJ, Baio G, Walters K, Petersen I, Limburg H, et al. (2011) Inequalities in the provision of cardiovascular screening to people with severe mental illness in primary care: Cohort study in the United Kingdom THIN Primary Care Database 2000-2007. Schizophrenia Research 129: 104-110.
13. Nazareth I, King M, Haines A, Rangel L, Myers S, (1993) Accuracy of diagnosis of psychosis on general practice computer system. BMJ 307: 32-34.
14. Bourke A, Dattani H, Robinson M, (2004) Feasibility study and methodology to create a quality-evaluated database of primary care data. Informatics in Primary Care 12 (3): 171-177.
15. Chisholm J, (1990) The Read clinical classification. BMJ 300 (6732): 1092.
16. Rait G, Walters K, Griffin M, Buszewicz M, Petersen I, et al. (2009) Recent trends in the incidence of recorded depression in primary care. The British Journal of Psychiatry 195 (6): 520-524.
17. Office for National Statistics website. Available: http://www.statistics.gov.uk/census2001/access_results.asp. Accessed 2011 August 01.
18. Townsend P, Phillimore P, Beattie A, (1986) Inequalities in health in the northern region. Newcastle upon Tyne Northern Regional Health Authority and University of Bristol.
19. Dave S, Petersen I, (2009) Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiology and Drug Safety 18 (8): 704-707.
20. Verdoux H, Tournier M, Begaud B, (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatrica Scandinavica 121 (1): 4-10.
21. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Marvin Swartz M, et al. (2006) Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6: 8.
22. NICE (2011 June 02) CG38 Bipolar disorder: review consultation document. Available: http://www.nice.org.uk/nicemedia/live/10990/54681/54681.pdf. Accessed 2011 August 01.
23. The BALANCE investigators and collaborators (2010) Lithium plus valproate Combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomized open-label trial. Lancet 375: 385-395.
24. Biel MG, Peselow E, Mulcare L, Case BG, Fieve R, (2007) Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disorders 9 (5): 435-442.
25. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK, (2011) Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. The British Journal of Psychiatry 199: 57-63.
26. Maj M, Pirozzi R, Magliano L, Bartoli L, (1998) Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 155 (1): 30-35.
27. Mander AJ, Loudon JB, (1998) Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 2: 15-17.
28. Goodwin GM, (1994) Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. The British Journal of Psychiatry 164: 149-152.
29. Castells X, Vallano A, Rigau D, Pérez J, Casas M, et al. (2006) Trends in lithium prescription in Spain from 1985 to 2003. Journal of Affective Disorders 91: 273-276.
30. Kaye JA, Bradbury BD, Jick H, (2003) Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. British Journal of Clinical Pharmacology 56 (5): 569-575.
31. Depp C, Ojeda VD, Mastin W, Unützer J, Gilmer TP, (2008) Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004. Psychiatr Serv 59 (10): 1169-1174.
32. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA, (2002) Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 159 (6): 1005-1010.
33. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, et al. (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467-1473.
34. Weisler RH, Ahearn EP, Davidson JR, Wallace CD, (1997) Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry 9: 259-262.
35. Ravindran AV, Jones BW, Al-Zaid K, Lapierre YD, (1997) Effective treatment of mania with olanzapine: 2 case reports. J Psychiatry Neurosci 22: 345-346.
36. Berk M, Ichim L, Brook S, (1999) Olanzapine compared to lithium in mania. A double-blind randomized controlled trial. Int Clin Psychopharmacol 14: 339-343.
37. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, et al. (1999) Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 156: 702-709.
38. Segal J, Berk M, Brook S, (1998) Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 21: 176-180.
39. Yatham LN, Paulsson B, Mullen J, Vagero AM, (2004) Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. Journal of clinical psychopharmacology 24 (6): 599.
40. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ, (1984) The fetal valproate syndrome. Am J Med Genet 19: 473-481.
41. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Cook M, et al. (2004) Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy-.
42. Holmes LB, Wyszynski DF, Lieberman ES, (2004) The AED (antiepileptic drug) Pregnancy Registry: a 6-year experience. Arch Neurol 61: 673-678.
43. Lloyd AJ, Harrison CL, Ferrier IN, Young AH, (2003) The pharmacological treatment of bipolar affective disorder: practice is improving but still could be better. J Psychopharmacol 17: 230-233.
44. Paton C, Barnes TRE, Shingleton-Smith A, McAllister-Williams HR, Kirkbride J, et al. (2010) Lithium in bipolar and other affective disorders: Prescribing practice in the UK. Journal of Psychopharmacology 24 (12): 1739-1746.
45. Saunders K, Goodwin GM, (2010) The course of Bipolar disorder. Advances in Psychiatric Treatment 16: 318-328.
46. Alda M, O'Donovan C, (2010) A much needed BALANCE. Bipolar Disorder 12: 678-680.